378 related articles for article (PubMed ID: 15459874)
1. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
2. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
4. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas.
Mashino K; Sadanaga N; Tanaka F; Yamaguchi H; Nagashima H; Inoue H; Sugimachi K; Mori M
Br J Cancer; 2001 Sep; 85(5):713-20. PubMed ID: 11531257
[TBL] [Abstract][Full Text] [Related]
5. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E
Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
7. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.
Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP
Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
9. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
12. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.
Yuasa T; Okamoto K; Kawakami T; Mishina M; Ogawa O; Okada Y
J Urol; 2001 May; 165(5):1790-4. PubMed ID: 11342977
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
15. Cancer/testis (CT) antigens: potential targets for immunotherapy.
Caballero OL; Chen YT
Cancer Sci; 2009 Nov; 100(11):2014-21. PubMed ID: 19719775
[TBL] [Abstract][Full Text] [Related]
16. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
17. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
[TBL] [Abstract][Full Text] [Related]
18. Potential target antigens for immunotherapy in human pancreatic cancer.
Schmitz-Winnenthal FH; Galindo-Escobedo LV; Rimoldi D; Geng W; Romero P; Koch M; Weitz J; Krempien R; Niethammer AG; Beckhove P; Buchler MW; Z'graggen K
Cancer Lett; 2007 Jul; 252(2):290-8. PubMed ID: 17320278
[TBL] [Abstract][Full Text] [Related]
19. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]